Tango Therapeutics shares are trading lower after Piper Sandler downgraded its rating on the stock from Overweight to Neutral and raised its price target from $16 to $24.

Benzinga Newsdesk www.benzinga.com Negative 96.8%

Neg 96.8% Neu 0% Pos 0%

Comments

No comments yet. Be the first!